A 45 year old man suffering from diabetes, high blood pressure and early kidney disease often keeps shuttling between three different specialists, an Endocrinologist, a cardiologist and a nephrologist, each focusing on one part of a single, connected problem. Cardiovascular Kidney Metabolic (CKM) syndrome, the term that links these conditions was first defined in 2023 by American Heart Association advisory.1
In 2026, the American College of Cardiology and the American Heart Association released the first comprehensive joint clinical guideline on CKM syndrome, making the 2013 obesity-management guideline redundant replacing the earlier 2013 AHA/ACC obesity management guideline as the primary framework for integrated cardiovascular-kidney-metabolic risk assessment.
The guidelines also include clinical staging criteria for CKM syndrome, screening protocols and treatment direction.2
The essence of CKM syndrome is the biochemical recognition of clinical realities. This involves the relationship between obesity, diabetes, chronic kidney disease, cardiovascular disease, and diseases such as heart failure, stroke, and peripheral artery disease.2 Dysfunctional adipose tissue may cause insulin resistance and inflammation, affecting heart, vessels and kidneys. In addition, poorly functioning kidneys can increase the risk of developing cardiovascular disease and the vicious cycle continues. After the term CKM syndrome came into existence, it is now clear that patients see multiple specialists, each following separate guidelines for the same underlying pathology.
In almost every diabetes or hypertension clinic, there are patients with early kidney damage that should have been caught years ago. The problem is tunnel vision, we keep treating these conditions as separate diagnoses and completely miss the bigger picture. South Asians tend to develop insulin resistance and cardiometabolic risk at lower body weights than Western populations, the so-called "thin-fat" phenotype, carrying more visceral fat and less muscle mass even at a BMI that would look unremarkable on paper.6 A pooled analysis of South Asian population puts general-population CKD prevalence at 14 percent, climbing to 31 percent among people with diabetes and 27 percent among people with hypertension.4 These numbers represent overlap between conditions and not CKM prevalence, as studies on this are yet to be done in India. Early CKM screening stops patients from crashing into end-stage disease by catching the warning signs early. Under the current system, a patient sees different specialists who each focus entirely on their own sandbox, stabilizing one organ while missing how that very dysfunction is quietly tanking the other two.
| Stage | Definition |
|---|---|
| Stage 0 | No CKM risk factors. Normal weight, glucose, BP, lipids, kidney function. Focus: primordial prevention. |
| Stage 1 | Excess or dysfunctional adipose tissue (overweight/obesity or prediabetes), no other metabolic risk factors, kidney disease, or CVD. |
| Stage 2 | One or more metabolic risk factors (hypertension, abnormal lipids, type 2 diabetes, metabolic syndrome) and/or kidney disease, without CVD. |
| Stage 3 | Subclinical (asymptomatic) CVD with CKM risk factors, OR very-high-risk CKD, OR high predicted 10-year CVD risk (PREVENT-CVD ≥20%). |
| Stage 4 | Diagnosed clinical CVD (coronary heart disease, heart failure, stroke, peripheral artery disease, atrial fibrillation) with overweight/obesity, other metabolic risk factors, or kidney disease. |
Most of the early stages have no symptoms, which is why the guideline recommends routine kidney testing for every adult. Specifically, eGFR and urine albumin-to-creatinine ratio (UACR), need to be checked together, as either test alone can miss what the other catches. Adding lipid panel and glucose panel to these could give inputs for assessing 10 and 30 year cardiovascular risk score, called PREVENT.
In the early stages, CKM risk factors can often improve significantly with lifestyle changes and appropriate treatment. How much they improve depends on a person's underlying health conditions and how early treatment begins. A preliminary trial at the AHA Scientific Sessions found that cutting calorie intake by 12%, limited or reversed CKM progression in young, healthy adults, though this is still unpublished, US based data.5 The guideline points to GLP-1 based therapies and SGLT2 inhibitors when drugs are indicated. The mainstay treatment guideline still remains lifestyle modifications including diet, physical activity, weight management and quitting smoking.
The condition was named back in 2023. What's new in 2026 is the guidelines for it by American Heart Association and The American College of Cardiology, which includes how to screen for it, diagnose it and management guidelines.
Yes, and often. Stages 0 through 2 are typically symptom-free, which is why routine screening has been suggested in the guidelines even when you feel completely fine.
No. Preliminary US data actually shows care costs for CKM rising fastest among people in their late twenties and early thirties, well before any diagnosis would normally happen.
Through routine eGFR and urine albumin-to-creatinine ratio testing, lipid and glucose panels, and a risk calculator, PREVENT, that estimates 10- and 30-year cardiovascular risk.
Note from the author: The tests included for the diagnosis including eGFR, lipid, and glucose panels are everyday routine ones that most labs already run. What's changed now is how these reports are to be interpreted together rather than separately. For patients splitting their care across three specialists, this guideline shifting from separate diagnosis to one connected risk profile, matters even more now than any new drug class in the market.
Ndumele, Chiadi E., Janani Rangaswami, Sheryl L. Chow, Ian J. Neeland, Katherine R. Tuttle, Salim S. Khan, Josef Coresh, et al. "Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the American Heart Association." Circulation 148, no. 20 (2023): 1606-1635.
American College of Cardiology and American Heart Association. "2026 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome." Journal of the American College of Cardiology (2026).
American Heart Association Newsroom. "First-Ever Guideline on Cardiovascular-Kidney-Metabolic Syndrome Issued." AHA News (2026).
Chronic Kidney Disease Burden in South Asian Populations: A Systematic Review and Meta-Analysis." PMC, National Center for Biotechnology Information (2021).
American Heart Association. "What Is CKM Syndrome, and Why Should Young Adults Pay Attention?" AHA News, December 1, 2025.
This article is for educational purposes and does not replace individualized medical advice. People with diabetes on medication, chronic kidney disease, cardiovascular conditions, or who are pregnant should consult their treating physician before making any changes based on this information.